Rifaximin — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Liver Disease

• Furosemide
• Lactulose
• Spironolactone
• Ursodiol

About Rifaximin

Rifaximin is a unique antibiotic that works primarily in your gut, offering targeted relief for various digestive conditions. If you've been prescribed rifaximin, you know its benefits are significant, but the cost can be a barrier. TheDrugClub is here to help, ensuring our members can access this vital medication with incredible savings.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Rifaximin is approved for (FDA label)

XIFAXAN is a rifamycin antibacterial indicated for: • Treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older. ( 1.1 ) • Reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. ( 1.2 ) • Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. ( 1.3 ) Limitations of Use TD: Should not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. ( 1.1, 5.1 ) 1.1 Travelers’ Diarrhea XIFAXAN is indicated for the treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adults and pediatric patients 12 years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Rifaximin (FDA label)

XIFAXAN is a pink-colored biconvex tablet and is available in the following strengths: • 200 mg – a round tablet debossed with “Sx” on one side and plain on the other. • 550 mg – an oval tablet debossed with “rfx” on one side and plain on the other. 200 mg and 550 mg tablets ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 7afafa63-3236-4212-9589-045db6b01c0b. SPL document ID: bb4000c2-f76a-42a8-8791-6730b748a3d4. Label effective date: August 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Rifaximin (FDA label)

The following clinically significant adverse reactions are described elsewhere in labeling: • Clostridium difficile -associated diarrhea [see Warnings and Precautions ( 5.2 )] Most common adverse reactions: • TD (≥2%): Headache ( 6.1 ) • HE (≥10%): Peripheral edema, nausea, constipation, dizziness, fatigue, urinary tract infection, insomnia, anemia, pruritus, and ascites ( 6.1 ) • IBS-D (≥2%): ALT increased, nausea ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 7afafa63-3236-4212-9589-045db6b01c0b. SPL document ID: bb4000c2-f76a-42a8-8791-6730b748a3d4. Label effective date: August 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Rifaximin (FDA label)

XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis [see Adverse Reactions ( 6.2 )] . History of hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components of XIFAXAN. ( 4) )

Source: FDA prescribing information (DailyMed). Set ID: 7afafa63-3236-4212-9589-045db6b01c0b. SPL document ID: bb4000c2-f76a-42a8-8791-6730b748a3d4. Label effective date: August 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Rifaximin (FDA label)

• Travelers’ Diarrhea Not Caused by E. coli : XIFAXAN was not effective in diarrhea complicated by fever and/or blood in the stool or diarrhea due to pathogens other than E. coli . If diarrhea symptoms get worse or persist for more than 24 to 48 hours, discontinue XIFAXAN and consider alternative antibiotics. ( 5.1 ) • Clostridium difficile -Associated Diarrhea: Evaluate if diarrhea occurs after therapy or does not improve or worsens during therapy. ( 5.2 ) • Hepatic Impairment: Use with caution in patients with severe (Child-Pugh Class C) hepatic impairment. ( 5.4 , 8.7 ) • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. ( 5.5, 7.1 ) 5.1 Travelers’ Diarrhea Not Caused by Escherichia coli XIFAXAN was not found to be effective in patients with diarrhea complicated by fever and/or blood in the stool or diarrhea due to pathogens other than Escherichia coli.

Source: FDA prescribing information (DailyMed). Set ID: 7afafa63-3236-4212-9589-045db6b01c0b. SPL document ID: bb4000c2-f76a-42a8-8791-6730b748a3d4. Label effective date: August 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Rifaximin (FDA label)

Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7.2 ) 7.1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed [see Warnings and Precautions ( 5.5 ), Clinical Pharmacology ( 12.3 )]. 7.2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range.

Source: FDA prescribing information (DailyMed). Set ID: 7afafa63-3236-4212-9589-045db6b01c0b. SPL document ID: bb4000c2-f76a-42a8-8791-6730b748a3d4. Label effective date: August 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.